Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL

Artiva Biotherapeutics (Nasdaq: ARTV) will present at the 2026 Transplantation & Cellular Therapy Tandem Meetings in Salt Lake City, Feb 4–7, 2026.

Rhea-AI Summary

Artiva Biotherapeutics (Nasdaq: ARTV) will present at the 2026 Transplantation & Cellular Therapy Tandem Meetings in Salt Lake City, Feb 4–7, 2026. Artiva will feature poster presentations on Feb 5, 2026 at 6:30 pm MST covering: the cost-effectiveness of AB-101/AlloNK administered in an outpatient community rheumatology practice versus CAR-T treatments, and continued durability data for AlloNK in relapsed/refractory Non-Hodgkin Lymphoma from a multi-center Phase 1/2 trial. Poster IDs are 440 (health services/cost-effectiveness) and 511 (lymphoma clinical durability); authors listed include Nicholas Veomett, Ph.D. and Umer Farooq, M.D. For full abstracts, consult the 2026 Tandem Meetings program.

Argus Jan 21 session

+2.81% close to close Open Argus

Details

News Market Reaction – ARTV

On Jan 21, the day this news came out, ARTV closed 2.81% above the previous close.

Data tracked by StockTitan Argus for the Jan 21 session.

Key Figures

Tandem Meetings dates: February 4–7, 2026 Poster ID: 440 Poster ID: 511 +2 more

Tandem Meetings dates

February 4–7, 2026

Transplantation & Cellular Therapy Meetings schedule

Poster ID

440

Cost-effectiveness of AB-101 vs CAR-T in rheumatologic diseases

Poster ID

511

Phase 1/2 AlloNK ± rituximab trial in NHL

Session time

6:30 pm MST

Poster sessions on Thursday, February 5, 2026

Trial phase

Phase 1/2

Multi-center AlloNK ± rituximab NHL trial

Historical Context

5 past events · Latest: Jan 08

5 events

1. Jan 08

   Leadership change

   24h Move

   -0.4%

   New CEO appointed to advance intracellular medicines platform.

2. Nov 12

   Clinical data update

   24h Move

   +10.9%

   Positive initial safety and B-cell depletion data for AlloNK in autoimmune.

3. Nov 12

   Earnings and pipeline

   24h Move

   +10.9%

   Q3 2025 results plus Fast Track designation and >100 patients treated.

4. Nov 03

   Data event preview

   24h Move

   -9.6%

   Announcement of virtual event to discuss initial AlloNK safety data.

5. Oct 30

   Investor conferences

   24h Move

   -10.3%

   Participation in November investor conferences with webcast access.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nk cell therapy, car-t treatments, phase 1/2, non-hodgkin lymphoma, +1 more

5 terms

nk cell therapy medical

"AB-101, an Off-the-Shelf NK Cell Therapy Administered in an Outpatient..."

NK cell therapy is a type of immune-based treatment that uses natural killer (NK) cells—a kind of white blood cell—to seek out and destroy abnormal cells such as cancer. Think of it as training and deploying guard dogs from the body’s immune system to target specific threats. It matters to investors because successful therapies can become high-value drugs, but they carry development, manufacturing and regulatory risks that affect potential returns.

car-t treatments medical

"Is More Cost-Effective Than CAR-T Treatments for Rheumatologic Diseases"

CAR-T treatments are medicines made by collecting a patient’s own immune cells, engineering them in a lab to recognize and attack specific cancer cells, and then infusing them back into the patient. They matter to investors because they can produce dramatic, long-lasting responses for hard-to-treat cancers but are costly, complex to manufacture, and face regulatory, reimbursement and scalability challenges that directly affect a developer’s revenue potential and profit margins.

phase 1/2 medical

"A Multi-Center, Phase 1/2 Trial of AlloNK ® Cell Therapy ± Rituximab"

Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.

non-hodgkin lymphoma medical

"AlloNK ® Cell Therapy ± Rituximab in Patients with Relapsed or Refractory Non ‑ Hodgkin Lymphoma"

A group of cancers that start in the lymphatic system, which is part of the body’s defense network of nodes and vessels; malignant cells multiply in lymph nodes, spleen or blood and can impair immune function. It matters to investors because diagnosis rates, available treatments, and regulatory approvals drive demand for drugs, influence clinical trial outcomes, and can shift revenue, development risk and valuation for companies in biotech, diagnostics and healthcare.

rituximab medical

"AlloNK ® Cell Therapy ± Rituximab in Patients with Relapsed or Refractory..."

Rituximab is a lab-made antibody drug that seeks out and removes a specific kind of white blood cell involved in certain blood cancers and autoimmune diseases, like a guided missile that finds its target. It matters to investors because regulatory approvals, clinical trial results, patent status and the arrival of lower-cost copies can sharply change sales, company value and future cash flow for firms that make or sell the therapy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a community rheumatology practice and continued durability of AlloNK in Non-Hodgkin Lymphoma (NHL).

The following abstracts will be presented as poster presentations at the 2026 Tandem Meetings:

Poster ID: 440	AB-101, an Off-the-Shelf NK Cell Therapy Administered in an Outpatient Community Rheumatology Practice, Is More Cost-Effective Than CAR-T Treatments for Rheumatologic Diseases
Poster Session:	Health Services and Barriers to Access
Date / Time:	Thursday, February 5, 2026, at 6:30 pm MST
Author:	Nicholas Veomett, Ph.D., Vice President, Corporate Development, Artiva Biotherapeutics
Poster ID: 511	A Multi-Center, Phase 1/2 Trial of AlloNK® Cell Therapy ± Rituximab in Patients with Relapsed or Refractory Non‑Hodgkin Lymphoma
Poster Session:	Lymphoma – Clinical
Date / Time:	Thursday, February 5, 2026, at 6:30 pm MST
Author:	Umer Farooq, M.D., Clinical Professor of Internal Medicine-Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa

For more information on these abstracts, visit the 2026 Tandem Meetings website.

About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK^® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren’s disease and an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs. 

Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (the “Tandem Meetings”), Artiva Biotherapeutics, Inc.’s (the “Company”) participation at the Tandem Meetings, and the Company’s mission, product candidates (including their potential to be cost effective, administrability in a community rheumatology practice, and durability), clinical trials, pipeline, and strategic partnerships. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Investors
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com

Media
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com

Source: Artiva Biotherapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Artiva (ARTV) present at the 2026 Tandem Meetings on February 5, 2026?

Artiva will present two posters on Feb 5, 2026 at 6:30 pm MST: cost-effectiveness of AB-101/AlloNK in community rheumatology and durability data for AlloNK in NHL.

Which Artiva poster discusses cost-effectiveness of AlloNK versus CAR-T for rheumatologic diseases?

Poster ID 440 (AB-101) covers the cost-effectiveness of AlloNK administered in an outpatient community rheumatology practice compared with CAR-T treatments.

Which Artiva poster reports durability of AlloNK in Non-Hodgkin Lymphoma (NHL)?

Poster ID 511 presents multi-center Phase 1/2 trial data on AlloNK ± rituximab showing continued durability in relapsed or refractory NHL.

Who are the listed authors for Artiva's 2026 Tandem Meeting posters (ARTV)?

The posters list Nicholas Veomett, Ph.D. and Umer Farooq, M.D. as authors for the respective presentations.

How can investors view Artiva's abstracts for the 2026 Tandem Meetings (ARTV)?

Investors can view the abstracts and poster details on the 2026 Tandem Meetings program website.